Ebola Virus Infection: a review on the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Clinical Pharmacokinetics Year : 2016

Ebola Virus Infection: a review on the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials

Abstract

The 2014-2015 outbreak of Ebola virus disease (EVD) is the largest epidemic to date in terms of number of cases, of death and affected areas. In October 2015, no antiviral agents had proven an antiviral efficacy in patients. However in September 2014 WHO inventoried and regularly updated since then a list of potential drug candidates with demonstrated antiviral efficacy in vitro or in animal models. This includes agents belonging to various therapeutic classes, namely direct antiviral agents (favipiravir and BCX4430), combination of antibodies (ZMapp), type I interferons, RNA interference-based drugs (TKM-Ebola and AVI-7537) and anticoagulant drug (rNAPc2). Here, we review the pharmacokinetic and pharmacodynamic information that are presently available on these drugs, using data obtained in healthy volunteers for pharmacokinetics and data obtained in human clinical trials or animal models for pharmacodynamics. Future studies evaluating these drugs in clinical trials will be critical to confirm their efficacy in humans, propose appropriate doses and evaluate the possibility of treatment combinations.
Fichier principal
Vignette du fichier
ClinicalPK_manuscript_final_hall.pdf (1.01 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-01344917 , version 1 (12-07-2016)

Identifiers

Cite

Vincent Madelain, Thi Huyen Tram Nguyen, Anaelle Olivo, Xavier de Lamballerie, Jeremie Guedj, et al.. Ebola Virus Infection: a review on the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clinical Pharmacokinetics, 2016, 55 (8), pp.907-23. ⟨10.1007/s40262-015-0364-1⟩. ⟨inserm-01344917⟩
311 View
738 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More